Blood pressure (BP) is one of the most important and common vascular risk factors but it is often poorly controlled. Inhibition of the renin-angiotensin-aldosterone system (RAAS) provides beneficial effects in hypertensives. The association of low-dosed diuretics in combination with RAAS blocking agents allows maximum benefit from potassium depletion and control of compensatory increase in renin secretion, so increasing the efficacy and safety of RAAS blockers. Irbesartan is a potent and selective angiotensin II subtype 1 receptor antagonist indicated for use in patients with hypertension, including those with type 2 diabetes mellitus and nephropathy. Once-daily irbesartan administration provides 24h control of BP. In patients with mild-to-...
The purpose of this study was to assess the safety and antihypertensive dose-response effects of irb...
Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively studied ...
Hypertension is a major risk factor for coronary heart disease, stroke, heart failure and renal dise...
Blood pressure (BP) is one of the most important and common vascular risk factors but it is often po...
Blood pressure is one of the most important and frequent risk factors for cardiovascular disease mor...
Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1...
Valentina Forni, Grégoire Wuerzner, Menno Pruijm, Michel BurnierService of Nephrology and...
<p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive...
Irbesartan is an orally active angiotensin II type 1 receptor antagonist (angiotensin receptor block...
In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetiti...
Irbesartan is a new selective angiotensin II subtype 1 receptor antagonist. We evaluated the efficac...
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of ...
Although an impressive array of efficacious antihypertensive agents are available to treat hypertens...
The angiotensin-receptor blockers (ARBs) are approvedby the Food and Drug Administration for treatme...
Abstract: Hypertension is one of the most important and prevalent major cardiovascular risk factors....
The purpose of this study was to assess the safety and antihypertensive dose-response effects of irb...
Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively studied ...
Hypertension is a major risk factor for coronary heart disease, stroke, heart failure and renal dise...
Blood pressure (BP) is one of the most important and common vascular risk factors but it is often po...
Blood pressure is one of the most important and frequent risk factors for cardiovascular disease mor...
Irbesartan is a long-acting angiotensin II antagonist acting specifically at the level of the Type 1...
Valentina Forni, Gr&eacute;goire Wuerzner, Menno Pruijm, Michel BurnierService of Nephrology and...
<p>Only few hypertensive patients are treated effectively despite of the variety of antihypertensive...
Irbesartan is an orally active angiotensin II type 1 receptor antagonist (angiotensin receptor block...
In this review, we discuss the pharmacological and clinical properties of irbesartan, a noncompetiti...
Irbesartan is a new selective angiotensin II subtype 1 receptor antagonist. We evaluated the efficac...
Giuseppe Derosa, Sibilla AT SalvadeoDepartment of Internal Medicine and Therapeutics, University of ...
Although an impressive array of efficacious antihypertensive agents are available to treat hypertens...
The angiotensin-receptor blockers (ARBs) are approvedby the Food and Drug Administration for treatme...
Abstract: Hypertension is one of the most important and prevalent major cardiovascular risk factors....
The purpose of this study was to assess the safety and antihypertensive dose-response effects of irb...
Irbesartan is an angiotensin II receptor (AT1 subtype) antagonist that has been extensively studied ...
Hypertension is a major risk factor for coronary heart disease, stroke, heart failure and renal dise...